Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (17)

« Back to Publications

Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT

Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 1 - 42

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial

Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 47 - 48

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial

Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 45 - 46

Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study)

Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 43 - 44

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.

Abhishek A. et al, (2024), Lancet Rheumatol, 6, e92 - e104

How should we best measure participant-reported ‘average hand pain’: comparison of two methods from a randomized placebo-controlled feasibility study of post-menopausal women with hand osteoarthritis

Williams JA. et al, (2023), Osteoarthritis and Cartilage, 31, s187 - s188

Hormone replacement therapy (conjugated oestrogens plus bazedoxifene) for post-menopausal women with symptomatic hand osteoarthritis: primary report from the HOPE-e randomised, placebo-controlled, feasibility study.

Williams JAE. et al, (2022), Lancet Rheumatol, 4, e725 - e737

Hand Osteoarthritis: investigating Pain Effects in a randomised placebo-controlled feasibility study of estrogen-containing therapy (HOPE-e): report on the primary feasibility outcomes

Williams J. et al, (2022), Annals of the Rheumatic Diseases, 81, 1616 - 1617

Hand Osteoarthritis: investigating Pain Effects of estrogen-containing therapy (HOPE-e): a protocol for a feasibility randomised placebo-controlled trial.

Marian IR. et al, (2021), Pilot Feasibility Stud, 7

In situ regeneration of retinal pigment epithelium by gene transfer of E2F2: a potential strategy for treatment of macular degenerations.

Kampik D. et al, (2017), Gene Ther, 24, 810 - 818

High Podocalyxin levels promote cell viability partially through up-regulation of Annexin A2.

San IVLC. et al, (2016), Biochem Biophys Res Commun, 478, 573 - 579

Regulation of C3 Activation by the Alternative Complement Pathway in the Mouse Retina.

Williams JAE. et al, (2016), PLoS One, 11

Exposure to the complement C5b-9 complex sensitizes 661W photoreceptor cells to both apoptosis and necroptosis.

Shi H. et al, (2015), Apoptosis, 20, 433 - 443

Retinal changes precede visual dysfunction in the complement factor H knockout mouse.

Williams JAE. et al, (2013), PLoS One, 8

Complement factor H deficiency results in decreased neuroretinal expression of Cd59a in aged mice.

Faber C. et al, (2012), Invest Ophthalmol Vis Sci, 53, 6324 - 6330

Load More